Immix Biopharma (Nasdaq:IMMX) - Stock Price, News & Analysis

IMMX Stock Overview

A clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia.

About the company

IMMX fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 72.8% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Earnings are forecast to decline by an average of 4.1% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 2 more risks

Immix Biopharma, Inc. Competitors

Vor Biopharma

NasdaqGS:VOR

US$59.8m

Intensity Therapeutics

NasdaqCM:INTS

US$59.9m

CollPlant Biotechnologies

NasdaqGM:CLGN

US$60.7m

Entera Bio

NasdaqCM:ENTX

US$60.7m

Price History & Performance

Summary of all time highs, changes and price drops for Immix Biopharma
Historical stock prices
Current Share Price	US$2.14
52 Week High	US$7.75
52 Week Low	US$1.75
Beta	0.17
11 Month Change	0%
3 Month Change	9.74%
1 Year Change	-6.55%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-41.69%

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Aug 12

Recent updates

Shareholder Returns

	IMMX	US Biotechs	US Market
7D	-0.5%	0.1%	0.07%
1Y	-6.6%	14.0%	22.7%

Return vs Industry: IMMX underperformed the US Biotechs industry which returned 14% over the past year.

Return vs Market: IMMX underperformed the US Market which returned 22.7% over the past year.

Price Volatility

Is IMMX's price volatile compared to industry and market?
IMMX volatility
IMMX Average Weekly Movement	13.2%
Biotechs Industry Average Movement	10.4%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Stable Share Price: IMMX has not had significant price volatility in the past 3 months.

Volatility Over Time: IMMX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2012	16	Ilya Rachman	www.immixbio.com

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd.

Immix Biopharma, Inc. Fundamentals Summary

How do Immix Biopharma's earnings and revenue compare to its market cap?
IMMX fundamental statistics
Market cap	US$58.74m
Earnings (TTM)	-US$19.02m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.1x

P/E Ratio

Is IMMX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMMX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$19.02m
Earnings	-US$19.02m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.69
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did IMMX perform over the long term?

See historical performance and comparison

IMMX Stock Overview

Rewards

Risk Analysis

Immix Biopharma, Inc. Competitors

NasdaqGS:VOR

US$59.8m

NasdaqCM:INTS

US$59.9m

NasdaqGM:CLGN

US$60.7m

NasdaqCM:ENTX

US$60.7m

Price History & Performance

Recent News & Updates

Immix Biopharma, Inc. Announces the Addition of Three Additional Clinical Trial Sites for Its U.S. Relapsed/Refractory Al Amyloidosis Clinical Trial NEXICART-2

Independent Director recently bought US$52k worth of stock

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Immix Biopharma, Inc. Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Insufficient new directors

New major risk - Revenue and earnings growth

Recent updates

Immix Biopharma, Inc. Announces the Addition of Three Additional Clinical Trial Sites for Its U.S. Relapsed/Refractory Al Amyloidosis Clinical Trial NEXICART-2

Independent Director recently bought US$52k worth of stock

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Immix Biopharma, Inc. Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Insufficient new directors

New major risk - Revenue and earnings growth

Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral Presentation

Immix Biopharma, Inc., Annual General Meeting, Jun 11, 2024

Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical Trial

New major risk - Shareholder dilution

Immix Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $14.999999 million.

New minor risk - Market cap size

Director recently bought US$267k worth of stock

Immix Biopharma, Inc. Announces New Clinical Data from Its Phase 1b/2a NEXICART-1

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Immix Biopharma, Inc. to Host KOL Event to Discuss Its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

New major risk - Financial position

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Immix Biopharma Inc. Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Director recently bought US$200k worth of stock

Immix Biopharma, Inc Announces U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma

Immix Biopharma, Inc. Appoints Yekaterina Chudnovsky as Member of the Board

Immix Biopharma, Inc. Reports 2Nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1B/2A Imx-110 Imx-110 Clinical Trial

Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?

We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate

Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer

Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

Immix Biopharma, Inc. Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

Immix Biopharma, Inc. Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX 110 in Advanced Solid Tumors

Immix Biopharma Announces Patient Dosing in Ongoing Phase 1B/2A Imx-110 Monotherapy Clinical Trial

Immix Biopharma, Inc. Releases and Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing

High number of new directors

Immix Biopharma, Inc. Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial

Immixbio Approves 4 Additional Clinical Trial Sites for Imx-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site

Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans

Immix Biopharma, Inc. Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials

Immix Biopharma, Inc. Announces Positive Interim Study Data Showing That After One Cycle of Treatment, Immixbio's Lead Candidate IMX-110 Produces 75% Survival Vs. 0% Survival for Trabectedin

We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely

High number of new and inexperienced directors

Immix Biopharma, Inc., Annual General Meeting, Jun 08, 2022

Immix Biopharma, Inc. Initiates Good Manufacturing Practice Manufacturing of IMX-120

Immix Biopharma, Inc. Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data

ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles

Immix Biopharma, Inc IMX-110 Produces 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study

U.S. Food and Drug Administration Approves Immix Biopharma, Inc. Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children

High number of new and inexperienced directors

Immix Biopharma, Inc. has completed an IPO in the amount of $21 million.

Shareholder Returns

Price Volatility

About the Company

Immix Biopharma, Inc. Fundamentals Summary

0.0x

-3.1x

Earnings & Revenue